BSE Live
Apr 20, 10:05Prev. Close
1492.80
Open Price
1505.60
Bid Price (Qty.)
1489.40 (5)
Offer Price (Qty.)
1505.30 (4)
NSE Live
Apr 20, 10:05Prev. Close
1491.00
Open Price
1530.00
Bid Price (Qty.)
1493.70 (1)
Offer Price (Qty.)
1497.10 (7)
| Profit & Loss account of Hester Biosciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 286.32 | 283.46 | 249.09 | 215.50 | 190.90 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 286.32 | 283.46 | 249.09 | 215.50 | 190.90 | |
| Total Operating Revenues | 286.47 | 285.16 | 254.00 | 219.35 | 208.48 | |
| Other Income | 4.76 | 4.26 | 5.32 | 4.66 | 1.65 | |
| Total Revenue | 291.23 | 289.42 | 259.32 | 224.01 | 210.13 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 38.86 | 32.69 | 29.28 | 34.93 | 24.18 | |
| Purchase Of Stock-In Trade | 44.84 | 56.60 | 55.37 | 39.30 | 25.21 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 9.97 | 10.36 | -4.77 | -12.53 | 4.01 | |
| Employee Benefit Expenses | 54.76 | 56.72 | 47.92 | 39.12 | 33.45 | |
| Finance Costs | 5.37 | 5.09 | 6.50 | 2.47 | 3.95 | |
| Depreciation And Amortisation Expenses | 8.58 | 9.78 | 9.79 | 9.50 | 9.63 | |
| Other Expenses | 87.10 | 81.45 | 71.32 | 57.96 | 49.64 | |
| Total Expenses | 249.47 | 252.69 | 215.40 | 170.75 | 150.06 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 41.76 | 36.73 | 43.92 | 53.26 | 60.06 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | -5.28 | |
| Profit/Loss Before Tax | 41.76 | 36.73 | 43.92 | 53.26 | 54.78 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 11.81 | 9.64 | 10.73 | 14.25 | 16.37 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.35 | -0.06 | 0.86 | -0.51 | -1.48 | |
| Tax For Earlier Years | -0.54 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 9.92 | 9.57 | 11.58 | 13.74 | 14.88 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 31.84 | 27.16 | 32.34 | 39.52 | 39.90 | |
| Profit/Loss From Continuing Operations | 31.84 | 27.16 | 32.34 | 39.52 | 39.90 | |
| Profit/Loss For The Period | 31.84 | 27.16 | 32.34 | 39.52 | 39.90 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 37.43 | 31.93 | 38.02 | 46.45 | 46.90 | |
| Diluted EPS (Rs.) | 37.43 | 31.93 | 38.02 | 46.45 | 46.90 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 5.10 | 6.81 | 8.51 | 8.51 | 5.62 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 70.00 | 60.00 | 80.00 | 100.00 | 100.00 |
03.02.2026
Hester Bio Consolidated December 2025 Net Sales at Rs 77.42 crore, up 22.46% Y-o-Y
03.02.2026
Hester Bio Standalone December 2025 Net Sales at Rs 70.35 crore, up 11.98% Y-o-Y
19.11.2025
Hester Bio Consolidated September 2025 Net Sales at Rs 70.97 crore, down 15.2% Y-o-Y
18.11.2025
Hester Bio Standalone September 2025 Net Sales at Rs 64.58 crore, down 12.14% Y-o-Y
03.02.2026
Hester Bio Consolidated December 2025 Net Sales at Rs 77.42 crore, up 22.46% Y-o-Y
03.02.2026
Hester Bio Standalone December 2025 Net Sales at Rs 70.35 crore, up 11.98% Y-o-Y
19.11.2025
Hester Bio Consolidated September 2025 Net Sales at Rs 70.97 crore, down 15.2% Y-o-Y
18.11.2025
Hester Bio Standalone September 2025 Net Sales at Rs 64.58 crore, down 12.14% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth